300896 Imeik Technology Development
- 219.01
- -1.38-0.63%
Imeik Technology Development News
The quarterly report verifies the strong growth in performance, why is Aimeike (300896.SZ) making strong players stronger?
In recent years, with the improvement of living standards, people have begun to pursue a higher level of spiritual life, and the face value economy has made great strides. According to a report published by Tencent Marketing Insights, the Chinese medical beauty market has grown at a compound annual growth rate of 17.5% since 2017 to nearly 190 billion dollars in 2021. However, due to multiple factors such as changes in residents' income expectations, the growth rate of medical and aesthetic consumption began to slow in 2022. The Zhitong Finance App notes that under the pessimistic expectations of the market, medicine and beauty have been questioned a lot over the past year or so as an “improved” optional consumption.
Ameke (300896.SZ) announced first-quarter results, net profit of 527 million yuan, an increase of 27.38%
According to the Zhitong Finance App, Aimeike (300896.SZ) released its report for the first quarter of 2024. During the reporting period, it achieved revenue of 808 million yuan, an increase of 28.24% over the previous year. Net profit attributable to shareholders of listed companies was $527 million, an increase of 27.38% over the previous year. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was $528 million, an increase of 36.53% over the previous year.
Aimeike (300896.SZ) plans to transfer 10 shares to 4 shares and send 23.23 yuan to cut interest on April 29
Ameke (300896.SZ) announced that the company plans to pay 23.23 yuan (tax included) for every 10 shares to all shareholders,...
Could The Market Be Wrong About Imeik Technology Development Co.,Ltd. (SZSE:300896) Given Its Attractive Financial Prospects?
It is hard to get excited after looking at Imeik Technology DevelopmentLtd's (SZSE:300896) recent performance, when its stock has declined 18% over the past month. However, stock prices are usually
The actual controllers of Ameke have made a profit, but what about shareholders?
“Investor Network” How profitable can a Jordan woman's face business be? From 2014 to 2023, Aimeike (300896.SZ), a “women's Maotai”, achieved leaps and bounds in performance by relying on products with a unit cost of only 20 to 30 yuan. The revenue scale increased from 75 million yuan to 2.9 billion yuan, and net profit also climbed from 28 million yuan to 1.9 billion yuan. Although the beautiful economy is attractive, the capital market is not an easy path. Aimeike went public with an overfunding of 1.5 billion yuan. At the beginning of its listing, it was enthusiastically sought after by the market, but now its market value has shrunk drastically, falling to more than 220 billion yuan. Not listed
Aimeike (300896.SZ): Pre-increase non-net profit by more than 30% in 2024Q1, forward-looking layout of the Blue Ocean Circuit
Aimeike, known as the “medical beauty”, seems to have recently faced quite a few challenges in the A-share market. Since April, its stock price has retreated nearly 15%, and its PE (TTM) has fallen to 34.67 times, setting a new low since listing. Naturally, this situation has attracted widespread attention in the market. (Data closes on April 9) However, when we delved deeper into the company's recently released earnings data, we saw a different picture. According to the 2023 annual report and the forecast for the first quarter of 2024, Aimec showed a steady growth trend. In 2023, the company achieved revenue of 2,869 billion yuan
Research Report Nuggets丨Everbright Securities: Aimeike's performance in the first quarter was in line with expectations and maintained a “buy” rating
According to the Everbright Securities Research Report, the opening performance of Aimeike (300896.SZ) in the first quarter was in line with expectations. According to the median revenue announced by the company, the company's Q1 revenue growth rate was 29.3% year over year. 2023Q1 is the first quarter where social activity fully resumed before the epidemic. After the Spring Festival ended in January 2023, from February to March 2023, society ushered in a strong recovery in consumption, and there was also a retaliatory rebound in consumption in the medical and aesthetic industry. On the basis of the high base of 2023Q1, the company's revenue growth rate in the first quarter was still close to 30% year-on-year, so I don't think the company started in '24
Ameke (300896.SZ): As of March 29, 2024, the number of shareholders of the company was 5,3651
Gelonghui, April 1 | Aimeike (300896.SZ) said on the investor interactive platform that as of March 29, 2024, the number of shareholders of the company was 53,651.
Shen Wan Hongyuan: The beauty market has entered a stage of steady development and is optimistic about the market space and performance transformation of key domestic brands
China's beauty market has left a decade of rapid growth and has entered a stage of steady development.
Here's What Analysts Are Forecasting For Imeik Technology Development Co.,Ltd. (SZSE:300896) After Its Full-Year Results
Imeik Technology Development Co.,Ltd. (SZSE:300896) shareholders are probably feeling a little disappointed, since its shares fell 2.1% to CN¥335 in the week after its latest annual results. Res
Ameke (300896.SZ): As of March 20, 2024, the number of shareholders of the company was 54,143
Gelonghui, March 21丨Aimeike (300896.SZ) said on the investor interactive platform that as of March 20, 2024, the number of shareholders of the company was 54,143.
Imeik Technology Development's Profit Rises 47% on Higher Revenue
Imeik Technology Development's (SHE:300896) attributable profit increased 47.1% to 1.86 billion yuan in 2023 from 1.26 billion yuan in 2022, according to a Wednesday filing with the Shenzhen bourse. T
How long can the American customer love myth of high growth last? | Insight Research
Despite 3 consecutive years of high performance growth, market concerns about Aimeike's future growth momentum have not been resolved.
Aimeike (300896.SZ): Net profit for 2023 increased by 47.08% to 1,888 billion yuan, plans to transfer 10 to 4 payments of 23.23 yuan
Glonghui, March 19 | Aimeike (300896.SZ) announced its 2023 annual report. During the reporting period, the company achieved annual operating income of 2,869 billion yuan, an increase of 47.99%; realized net profit attributable to shareholders of listed companies of 1,888 billion yuan, an increase of 47.08%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 1,831 billion yuan, an increase of 52.95% year on year; basic income per share was 8.60 yuan; it is intended to distribute cash dividends of 23.23 yuan (tax included) for every 10 shares to all shareholders, using capital reserves All shareholders increase for every 10 shares
Aimeike (300896.SZ): The company has not carried out AI medical and aesthetic projects
Gelonghui March 12 | Aimeike (300896.SZ) said on the investor interactive platform that the company has not carried out AI medical and aesthetic projects.
Imeik Technology Development Co.,Ltd. (SZSE:300896) Adds CN¥3.3b in Market Cap and Insiders Have a 43% Stake in That Gain
Key Insights Significant insider control over Imeik Technology DevelopmentLtd implies vested interests in company growth The top 5 shareholders own 52% of the company Institutions own 16% of Imei
Ameke (300896.SZ): As of February 8, 2024, the number of shareholders of the company was 52,183
Gelonghui, Feb. 19 | Aimeike (300896.SZ) said on the investor interactive platform that as of February 8, 2024, the number of shareholders of the company was 52,183.
Light medical beauty has become a New Year's item. Are you beautiful today? ｜Lunar New Year Planning
“Investor Network” Jordan During the Spring Festival, the medical and aesthetic industry is always extremely prosperous. As consumer attitudes change, high-tech beauty projects such as water light, thermage, and hyaluronic acid are becoming more and more popular, and more people are willing to invest time and money to improve their appearance during the Spring Festival. At a beauty salon in Guangzhou's Yuexiu District, Ms. Su, who was waiting for service, told “Investor Network”, “I came here on purpose to get a water light needle to make me look a little better and stay beautiful in spring.” In recent years, technological beauty has begun to show great potential and has become a golden racetrack in the consumer industry. According to data from the China Business Industry Research Institute, China's medical beauty in 2022
Imeik Technology Development Co.,Ltd. (SZSE:300896) Shares Could Be 26% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Imeik Technology DevelopmentLtd fair value estimate is CN¥430 Current share price of CN¥318 suggests Imeik Technology DevelopmentLtd is poten
Aimeike (300896.SZ): The injectable botulinum toxin project is a product of South Korea's Huons company
Gelonghui, January 29丨Aimeike (300896.SZ) said on the investor interactive platform that the injectable type A botulinum toxin project is a product represented by South Korea's Huons.
Analysis
Price Target
No Data
